Evidence map›Paper›PMID 37296110›Full record

ArticleNature communications2023

Persistent serum protein signatures define an inflammatory subcategory of long COVID.

Aarthi Talla, Suhas V Vasaikar, Gregory Lee Szeto, Maria P Lemos, Julie L Czartoski, Hugh MacMillan, Zoe Moodie, Kristen W Cohen, Lamar B Fleming, Zachary Thomson and 10 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 2 pooled it
25.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 2 syntheses or guidelines pooled it, 120 citations in OpenAlex.

  1. Impact of air pollution on COVID-19 severity: a systematic review of underlying biological mechanisms.European respiratory review : an official journal of the European Respiratory Society · 2025
    Pooled it
  2. Pathophysiological Mechanisms in Long COVID: A Mixed Method Systematic Review.International journal of environmental research and public health · 2024
    Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Observational
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. CD4Frontiers in immunology · 2026
    Article

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 3 institutions in 2 countries.

Aarthi Talla *Allen Institute for Immunology, Seattle, WA, USA.
Suhas V Vasaikar *Allen Institute for Immunology, Seattle, WA, USA.
Gregory Lee SzetoAllen Institute for Immunology, Seattle, WA, USA.
Maria P LemosVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Julie L CzartoskiVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Hugh MacMillanVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID 0000-0003-3661-2212
Zoe MoodieVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID 0000-0001-8701-2001
Kristen W CohenVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID 0000-0002-8901-9941
Lamar B FlemingVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID 0000-0002-6180-5545
Zachary ThomsonAllen Institute for Immunology, Seattle, WA, USA.ORCID 0000-0002-3861-9998
Lauren OkadaAllen Institute for Immunology, Seattle, WA, USA.
Lynne A BeckerAllen Institute for Immunology, Seattle, WA, USA.ORCID 0000-0003-1541-4655
Ernest M CoffeyAllen Institute for Immunology, Seattle, WA, USA.
Stephen C De RosaVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Evan W NewellVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID 0000-0002-2889-243X
Peter J SkeneAllen Institute for Immunology, Seattle, WA, USA.
Xiaojun LiAllen Institute for Immunology, Seattle, WA, USA.ORCID 0000-0003-0832-9479
Thomas F BumolAllen Institute for Immunology, Seattle, WA, USA. tbumol@gmail.com.ORCID 0000-0003-4319-1006
M Juliana McElrathVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. jmcelrat@fredhutch.org.
Troy R TorgersonAllen Institute for Immunology, Seattle, WA, USA. troy.torgerson@alleninstitute.org.ORCID 0000-0003-3489-5036
Allen Institute for Immunology · USFred Hutch Cancer Center · USCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa · ZA

Funding

LC: HIV Vaccine Trials NetworkUM1AI068618 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Margaret Juliana McElrath · 2011 to 2026
$483.6M
SDMC: HIV Vaccine Trials NetworkUM1AI068635 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert, Yunda Huang · 2011 to 2026
$385.9M
Seattle Vaccine Trials UnitUM1AI069481 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Rachel Ann Bender Ignacio, Margaret Juliana McElrath · 2012 to 2026
$24.4M
NIAID NIH HHS UM1 AI068618NIAID NIH HHS UM1 AI068635NIAID NIH HHS UM1 AI069481
6 · The paper itself

Abstract

Long COVID or post-acute sequelae of SARS-CoV-2 (PASC) is a clinical syndrome featuring diverse symptoms that can persist for months following acute SARS-CoV-2 infection. The aetiologies may include persistent inflammation, unresolved tissue damage or delayed clearance of viral protein or RNA, but the biological differences they represent are not fully understood. Here we evaluate the serum proteome in samples, longitudinally collected from 55 PASC individuals with symptoms lasting ≥60 days after onset of acute infection, in comparison to samples from symptomatically recovered SARS-CoV-2 infected and uninfected individuals. Our analysis indicates heterogeneity in PASC and identified subsets with distinct signatures of persistent inflammation. Type II interferon signaling and canonical NF-κB signaling (particularly associated with TNF), appear to be the most differentially enriched signaling pathways, distinguishing a group of patients characterized also by a persistent neutrophil activation signature. These findings help to clarify biological diversity within PASC, identify participants with molecular evidence of persistent inflammation, and highlight dominant pathways that may have diagnostic or therapeutic relevance, including a protein panel that we propose as having diagnostic utility for differentiating inflammatory and non-inflammatory PASC.

Indexed as

COVID-19Post-Acute COVID-19 SyndromeBlood ProteinsDisease ProgressionHumansInflammationSARS-CoV-2Blood Proteins

Identifiers

PMID37296110
PMCPMC10252177
OpenAlexW4380089742

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.